Abstract
Objective To investigate the significance of c-myc gene rearrangement on the long term efficacy of diffuse large B-cell lymphoma (DLBCL), and to provide the evidence-based medicine for prognosis of DLBCL. Methods The Chinese and English database were searched to identify all the articles about the DLBCL with c-myc gene rearrangement by computer. Meta-analysis was completed by RevMan 5.2 software. Results A total of eight studies were included. The Meta-analysis results displayed that DLBCL patients with c-myc gene rearrangement had the poor prognosis. Five years progression free survival (PFS) and overall survival (OS) were significantly worse (HR= 2.28, 95% CI 1.64-3.18 and HR= 2.35, 95% CI 1.93-2.85). Conclusion C-myc gene rearrangement is a potential biomarker for the poor prognosis of DLBCL. Key words: Gene, c-myc; Lymphoma, large B-cell, diffuse; Prognosis; Meta analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
